NCT05019898

Brief Summary

Given the difficulties encountered with subjective pain assessment tools, one of the ideas for reducing the occurrence of insufficient analgesia administration in the emergency department is to find a tool capable of measuring pain without requiring the patient's participation, and which could be integrated into the systematic measurement of the 4 other vitals. An interesting idea is the measurement of pupillary diameter and its reflex variations by a portable pupillometer. Indeed, the diameter of the pupil (DP) reflects the constant interactions between the sympathetic and parasympathetic systems at the level of the iris muscles. Pupillometry measures the change in pupillary diameter and allows the performance of three dynamic tests useful in the assessment of pain.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
320

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 4, 2021

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

August 10, 2021

Completed
15 days until next milestone

First Posted

Study publicly available on registry

August 25, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2022

Completed
3 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 4, 2022

Completed
Last Updated

August 25, 2021

Status Verified

August 1, 2021

Enrollment Period

12 months

First QC Date

August 10, 2021

Last Update Submit

August 24, 2021

Conditions

Keywords

pupillometry

Outcome Measures

Primary Outcomes (1)

  • The primary outcome will be the correlation between the pupillometry values and those obtained by the numerical pain rating scale with a correlation coefficient of 0.78.

    1 minute

Secondary Outcomes (6)

  • The evolution of the Pupillary Unrest in Ambient Light depending on the type of opioid (morphine versus weak opioid like tramadol) received by the patient.

    one hour

  • The endpoint will be the evaluation of the performance of pupillometry to predict the occurrence of Numerical Rating Scale (NRS) ≥ 4 using the ROC curve (AUC).

    1 minute

  • The correlation of the pupillometric parameters with the level of anxiety quantified by a numeric scale next to 1 (not anxious) to 10 (maximum level of anxiety).

    1 minute

  • The correlation between the initial measurement of PUAL and the analgesic response to an opioid medication.

    one hour

  • The correlation between the pain measurements obtained by the reception nurse and that obtained by the patient.

    2 minutes

  • +1 more secondary outcomes

Study Arms (1)

Diagnostic Test: pupillometry

EXPERIMENTAL
Diagnostic Test: pupillometry

Interventions

pupillometryDIAGNOSTIC_TEST

Step 1: The triage will be carried out by the nurse. The nurse will then perform a self-assessment of the patient's pain using a simple verbal scale. The nurse will then record the patient's self-assessment of his pain using the numeric scale for pain. Step 2: Immediately after this first assessment, eligible patients will be approached by the study investigator to be included in the study. Step 3: If the patient gives informed consent, the study investigator will perform * The quantification of their anxiety * An assessment of pain by a NeuroLight videopupillometer (iDmed, Marseille, France) using two dynamic tests, the Pupillary Unrest in Ambient Light (PUAL) and the pupillary light reflex. Step 4: One hour after the triage, a second pain assessment will be performed. Step 5: The same pupillometry measurements will be taken immediately after the nurse has assessed the pain.

Diagnostic Test: pupillometry

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients presenting to the emergency room, aged 18 years or over, able to communicate, with hemodynamic and respiratory stability, are eligible.

You may not qualify if:

  • \- Refusal to participate in the study; refusal to sign informed consent.
  • Consent impossible to obtain (cognitive disorders, language barrier…).
  • Patient taking immediate-release opioid medication (last dose within the last 12 hours).
  • Patient taking prolonged-release opioid medication (last dose within the last 24 hours).
  • Basic treatment with a dopaminergic D2 antagonist (antipsychotic drugs).
  • Basic treatment with dopamine antagonist antiemetic medication (metoclopramide (T1/2 5-6h), domperidone (T1/2 7-9h), alizapride (T1/2 3h)) within the last 12 hours.
  • Patient taking clonidine (last dose within the last 24 hours).
  • Use of topical ocular drugs modifying pupillary parameters in the last 24 hours.
  • Bilateral eye surgery modifying the possibilities of variation in pupillary diameter bilaterally.
  • Parkinson's or Alzheimer's disease at a dysautonomic stage.
  • Admission to the emergency room for acute ocular pathology.
  • History of diabetes at a dysautonomic stage.
  • History of alcoholism at a dysautonomic stage.
  • History of glaucoma.
  • Pregnant patient with preeclampsia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

cliniques universitaires Saint-Luc

Brussels, 1200, Belgium

RECRUITING

Related Publications (1)

  • Gregoire C, Charier D, de Bergeyck R, Mouraux A, Van Ouytsel F, Lambert R, Zhou N, Lavand'homme P, Penaloza A, Pickering G. Comparison between pupillometry and numeric pain rating scale for pain assessments in communicating adult patients in the emergency department. Eur J Pain. 2023 Sep;27(8):952-960. doi: 10.1002/ejp.2137. Epub 2023 Jun 11.

MeSH Terms

Conditions

Acute Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 10, 2021

First Posted

August 25, 2021

Study Start

August 4, 2021

Primary Completion

August 1, 2022

Study Completion

August 4, 2022

Last Updated

August 25, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations